All Autoimmune Gastritis Are Not Created the Same

Massimo RUGGE1,2*, Robert M GENTA3, Ludovica BRICCA2,3,4 and Edoardo SAVARINO4

1Department of Medicine (DIMED), Surgical Pathology & Cytopathology Unit, Padova University, Italy
2Veneto Tumor Registry (RTV), Veneto Regional Authority, Italy
3Department of Pathology, Michael E DeBakey VA Medical Center, Baylor College of Medicine, Houston, USA
4Department of Surgical Oncological & Gastroenterological Sciences (DISCOG), Gastroenterology Unit, Padua University, Italy

Keywords
Autoimmune gastritis, Gastric cancer, MSH2/MLH1, Mismatch repair (MMR) system

Introduction

We read with great interest the outstanding scientific paper recently published in Gastroenterology Research by David Saulino and colleagues, entitled “Characterization of Chronic Gastritis in Lynch Syndrome Patients with Gastric Adenocarcinoma” [1]. By concluding that “… most gastric adenocarcinoma in Lynch Syndrome patients were located in the fundus and/or body …, with a tumorigenesisis of chronic gastritis (immune gastritis in most cases and H. pylori gastritis in the minority of cases)-associated intestinal metaplasia, dysplasia, and carcinoma”, the Authors suggest gastric autoimmunity as electively involved in gastric oncogenesis.

Because of our long-standing interest in the still controversial assessment of gastric cancer risk association with autoimmune gastritis, we would like to briefly comment on the results and the conclusions of the paper by Saulino, et al. [1-5].

The increased risk of gastric cancer (GC) in Lynch syndrome is well established. In their manuscript Saulino, et al. further support the hypothesis, previously put forward by Adar, et al. of a causative relationship between MSH2 mutation (as observed in mismatch repair-related Lynch syndrome) and autoimmune gastritis, and -as a consequence- between autoimmune gastritis and gastric adenocarcinoma [6-8].

In a retrospective series of 562 histologically consistent, serologically confirmed autoimmune gastritis, we detected neoplastic lesions (both non-invasive and invasive) in only 4 high-stage gastritis patients (Operative Link on Gastritis Assessment [OLGA] stages III and IV), 3 of whom with a history of H. pylori infection [2,7]. In a second long-term prospective follow-up study (data on file) of 258 patients with autoimmune gastritis who tested negative for H. pylori infection (H. pylori-serology and molecular testing on gastric biopsy tissue specimens) and assessed by paired endoscopy/histology, 2 cases of low-grade gastric dysplasia were histologically assessed, invasive gastric epithelial malignancies were never documented, and only 2 cancer cases (1 breast, and 1 lung) emerged during a mean follow-up time of 7 years (range: 2-17 years). Neither of these figures supports an increased risk of gastric cancer in patients with autoimmune gastritis, particularly when an etiological involvement of H. pylori is excluded.

In keeping with previous findings by Adar, et al. [6], the cohort of gastric cancer patients described by Saulino refers to a very peculiar biological-clinical setting, characterized by the combination of a cancer-promoting genetic profile (MSH2/MLH1 abnormality) with an autoimmune-based gastritis [1].

The loss of function/mutation of MSH2 (one of the most involved genetic defects resulting into Lynch’s syndrome) has been consistently included among the features associated with increased tumor mutational burden (TMB), which is - in turn - involved in T-cell response against tumor cells [4,8-10]. Such a biological setting evokes the hypothesis of a common “syndromic” background (mismatch repair [MMR] genes deficiency) for both Lynch syndrome and autoimmune diseases [11,12]. Such an intriguing theory, however, cannot, per se, support linking the entire spectrum of autoimmune gastritis to MMR, ultimately associating (longstanding) gastric dysplasia with increased risk of gastric cancer in patients with autoimmune gastritis.
autoimmunity to a significantly increased risk of gastric cancer.

Among the 11 patients included in the Saulino’s study (after excluding three cases with reactive gastropathy or normal antrum), five featured the inflammatory/atrophic involvement of the antral mucosa, and no information is provided on the antral mucosa of the three remaining patients [1]. While these features do not exclude a potential role for gastric autoimmunity in the onset of gastric cancer, they leave still open the question of the role of H. pylori infection (active, previous, or undetected) as co-responsible for the concretization field in which gastric cancer mostly develops.

In conclusion, the results obtained by Saulino, et al. stimulate interesting speculations on the biological relationships between Lynch syndrome, a subset of autoimmune gastritis, and non-gastric autoimmune diseases. These results, however, should be interpreted carefully before suggesting that non-Lynch-associated (i.e. “non-syndromic”) autoimmune gastritis could be a significant determinant in increasing the risk for gastric cancer.

Acknowledgements
Not applicable.

Financial Disclosure or Funding
Authors have no financial disclosure to report.

Conflict of Interest
The authors declare that they have no conflict of interest.

Informed Consent
Not applicable.

Author Contributions
Massimo Rugge: Critical evaluation of the manuscript to which the LETTER TO THE EDITOR is addressed. Drafting the manuscript and approval of the final version of the submitted manuscript; Robert M Genta: Critical evaluation of the manuscript to which the LETTER TO THE EDITOR is addressed. Drafting the manuscript and approval of the final version of the submitted manuscript; Ludovica Bricca: Critical evaluation of the available literature on the addressed topic; drafting of the manuscript and approval of the final version of the manuscript; Edoardo Savarino: Critical evaluation and approval of the final version of the Submitted manuscript.

Data Availability
The author declares that data supporting the findings of this study are available within the article.

- The authors declare that data supporting the findings of this study are available within the article.
- The data supporting the findings of this study are available from the corresponding author upon reasonable request.
- Any inquiries regarding supporting data availability of this study should be directed to the corresponding author.

References
1. Saulino D, Chen R, Wang K, et al. (2021) Characterization of chronic gastritis in Lynch syndrome patients with gastric adenocarcinoma. Gastroenterology Res 14: 13-20.
2. Rugge M, Fassan M, Pizzi M, et al. (2012) Autoimmune gastritis: Histology phenotype and OLGA staging. Aliment Pharmacol Ther 35: 1460-1466.
3. Song M, Latorre G, Ivanovic-Zuvic D, et al. (2009) Autoimmune diseases and gastric cancer risk: A systematic review and meta-analysis. Cancer Res Treat 51: 841-850.
4. Lentzi MV, Rugge M, Lahner E, et al. (2020) Autoimmune gastritis. Nat Rev Dis Primers 6: 56.
5. Rugge M (2020) Gastric cancer risk: Between genetics and lifestyle. Lancet Oncol 21: 1258-1260.
6. Adar T, Friedman M, Rodgers LH, et al. (2019) Gastric cancer in Lynch syndrome is associated with underlying immune gastritis. J Med Genet 56: 844-845.
7. Rugge M, Savarino E, Sbaraglia M, et al. (2021) Gastritis: The clinicopathological spectrum. Dig Liver Dis 53: 1237-1246.
8. Park DJ, Park SH, Kim SH, et al. (2005) Effect of helicobacter pylori infection on the expression of DNA mismatch repair protein. Helicobacter 10: 179-184.
9. Jia M, Yao L, Yang Q, et al. (2020) Association of msh2 expression with tumor mutational burden and the immune microenvironment in lung adenocarcinoma. Front Oncol 10: 168.
10. Tamura K, Kaneda M, Futagawa M, et al. (2019) Genetic and genomic basis of the mismatch repair system involved in Lynch syndrome. Int J Clin Oncol 24: 999-1011.
11. Muro Y, Sugiuura K, Mimori T, et al. (2015) DNA mismatch repair enzymes: Genetic defects and autoimmunity. Clin Chim Acta 442: 102-109.
12. Toledano H, Orenstein N, Sofrin E, et al. (2019) Paediatric systemic lupus erythematosus as a manifestation of constitutional mismatch repair deficiency. J Med Genet 57: 505-508.

DOI: 10.36959/621/624